Somatostatin Receptor Subtype Expression in Human Thyroid Tumours

Abstract

Somatostatin receptors (SSTR) are expressed in various endocrine tumours. The expression of SSTR at the tumour cell surface confers the possibility for diagnostic imaging and therapy of tumours using radiolabeled somatostatin analogues. The majority of currently available somatostatin analogues show a higher binding affinity for the SSTR2 subtype. To date, the precise expression pattern of the SSTR subtypes 1–5 in thyroid epithelial tumours remains to be determined. We investigated the mRNA expression of SSTR1-5 in benign and malignant epithelial thyroid tumours [20 cold thyroid nodules (CTNs), 20 toxic thyroid nodules (TTNs), 20 papillary, 20 follicular, and 5 anaplastic carcinomas (PTCs, FTCs, ATCs, respectively)] and compared them to normal surrounding thyroid tissues. Four out of five SSTR subtypes were detected in malignant thyroid tumours, benign neoplasia, and normal surrounding tissue with a predominant expression of SSTR2 and SSTR5, and a weak expression of SSTR1 and SSTR3. Weak SSTR4  mRNA expression was detected in some PTCs. Compared to normal thyroid tissue, SSTR2 was significantly upregulated in PTC and ATC. In addition significant upregulation of SSTR3 was found in PTC. SSTR5 mRNA expression was increased in PTC and FTC and significantly decreased in CTN and TTN compared to normal thyroid tissue. SSTR2 is the predominant subtype in thyroid epithelial tumours with a high expression pattern, in particular, in PTC. Perspectively, the expression of distinct SSTR in thyroid epithelial tumours might represent a promising avenue for diagnostics and therapy of advanced thyroid cancer with somatostatin analogues.

Key words

cancer - neoplasia - somatostatin analogues - octreotide

References

• 1 Reubi JC, Krenning E, Lamberts SW, Kvols L. Somatostatin receptors in malignant tissues.  J Steroid Biochem Mol Biol. 1990;  20 1073-1077
• 2 Bruns C, Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Hoyer D, Lubbert H. Molecular pharmacology of somatostatin-receptor subtypes.  Ann N Y Acad Sci. 1994;  733 138-146
• 3 Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family.  Life Sci. 1995;  57 1249-1265
• 4 Druckenthaner M, Schwarzer C, Ensinger C, Gabriel M, Prommegger R, Riccabona G, Decristoforo C. Evidence for Somatostatin Receptor 2 in Thyroid Tissue.  Regul Pept. 2007;  138 32-39
• 5 Ain KB, Taylor KD, Tofiq S, Venkataraman G. Somatostatin Receptor Subtype Expression in Human Thyroid and Thyroid Carcinoma Cell Lines.  J Clin Endocrinol Metab. 1997;  82 1857-1862
• 6 Forssell-Aronsson EB, Nilsson O, Bejegard SA, Kolby L, Bernhardt P, Molne J, Hashemi SH, Wangberg B, Tisell LE, Ahlman H. 111In-DTPA-D-Phe1-Octreotide binding and somatostatin receptor subtypes in thyroid tumors.  J Nucl Med. 2000;  41 636-642
• 7 Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin Analogs for Diagnosis and Treatment of Cancer.  Pharmacol Ther. 1993;  60 245-264
• 8 Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic Use.  Eur J Nucl Med. 2000;  27 273-282
• 9 Corleto VD, Falconi M, Panzuto F, Milione M, De Luca O, Perri P, Cannizzaro R, Bordi C, Pederzoli P, Scarpa A, Delle FG. Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas.  Neuroendocrinology. 2009;  89 223-230
• 10 Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, Schindler M, Cole SL, Bussolati G. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic rndocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis.  Virchows Arch. 2002;  440 461-475
• 11 Lamberts SW, Hofland LJ; van Koetsveld PM, Reubi JC, Bruining HA, Bakker WH, Krenning EP. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: Consequences with Regard to diagnosis, localization, and therapy.  J Clin Endocrinol Metab. 1990;  71 566-574
• 12 Nilsson O, Kolby L, Wangberg B, Wigander A, Billig H, William-Olsson L, Fjalling M, Forssell-Aronsson E, Ahlman H. Comparative studies on the expression of somatostatin receptor subtypes, Outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.  Br J Cancer. 1998;  77 632-637

Correspondence